

Special Issue

Antimicrobial Prescribing Practices and Antimicrobial Resistance in the COVID-19 Pandemic

Message from the Guest Editor

The syndemic impact of COVID-19 affected several fields of healthcare, and antimicrobial resistance is among them. Recent international reports reveal a transient decrease in some community-acquired pathogens in the first year of the pandemic with an increase thereafter, pointing to the role of infection prevention in the general population, including hygiene and vaccination. At the same time, we have observed a general increase in typical hospital-acquired pathogens. In addition, many countries report critical increases in some extremely resistant pathogens such as carbapenem-resistant *Klebsiella pneumoniae* and carbapenem-resistant *Acinetobacter baumannii*. As the pandemic has slowly started to calm down, the hidden pandemic of antimicrobial resistance remains and requires increased effort in infection control and antimicrobial stewardship. To support antimicrobial stewardship interventions, careful analysis of what transpired is needed. The focus of this Special Issue includes various aspects of antibiotic use during the COVID-19 pandemic in outpatients, hospitals, ICU wards, as well as antibiotic treatment in patients with COVID-19.

Guest Editor

Prof. Dr. Bojana Beović

Department of Infectious Diseases, University Medical Centre Ljubljana, Zaloška cesta 2, 1000 Ljubljana, Slovenia

Deadline for manuscript submissions

closed (31 March 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/151642

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)